PR Newswire BiotechOriginal article
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
Phase 1positiveSKY-0515Positive
AI Analysis
Summary
Skyhawk Therapeutics announced final fifteen-month results from its Phase 1/2 trial of SKY-0515 in Huntington's Disease patients, showing a +1.59-point difference in cUHDRS change from baseline at the primary endpoint. The positive Phase 1/2 data represents potential clinical progress for the neurodegenerative disease indication.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Met
Outcome Details
SKY-0515-treated patients showed +1.59-point difference in cUHDRS change from baseline at Month 15 primary timepoint
Importance:6/10
Sentiment:
0.60
Phase 1/2Huntington's DiseaseClinical Trial ResultscUHDRSData Readout
Read the original article
Published by PR Newswire Biotech on September 15, 2026 4:46 PM